(Q41863153)

13 October 2017

Potent antihyperglycaemic property of a new imidazoline derivative S-22068 (PMS 847) in a rat model of NIDDM. (English)

1 reference

13 October 2017

0 references

Pelé-Tounian A

1

1 reference

13 October 2017

Wang X

2

1 reference

13 October 2017

Rondu F

3

1 reference

13 October 2017

Lamouri A

4

1 reference

13 October 2017

Touboul E

5

1 reference

13 October 2017

Marc S

6

1 reference

13 October 2017

Dokhan R

7

1 reference

13 October 2017

Pfeiffer B

8

1 reference

13 October 2017

Manechez D

9

1 reference

13 October 2017

Renard P

10

1 reference

13 October 2017

Guardiola-Lemaître B

11

1 reference

13 October 2017

Godfroid JJ

12

1 reference

13 October 2017

Pénicaud L

13

1 reference

13 October 2017

Ktorza A

14

1 reference

13 October 2017

language of work or name

English

0 references

publication date

1 August 1998

1 reference

British Journal of Pharmacology

13 October 2017

1 reference

13 October 2017

124

1 reference

13 October 2017

8

1 reference

13 October 2017

1591-1596

1 reference

Antagonism of the stimulatory effects of efaroxan and glibenclamide in rat pancreatic islets by the imidazoline, RX801080.

13 October 2017

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701989

The imidazoline site involved in control of insulin secretion: characteristics that distinguish it from I1- and I2-sites.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701989

Characterization and autoradiographical localization of non-adrenoceptor idazoxan binding sites in the rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701989

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701989

7 January 2021

Insulin resistance in skeletal muscles in patients with NIDDM.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701989

7 January 2021

Antazoline increases insulin secretion and improves glucose tolerance in rats and dogs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701989

7 January 2021

Evidence for a direct stimulatory effect of cibenzoline on insulin secretion in rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701989

7 January 2021

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701989

7 January 2021

Alpha-adrenergic blockade improves glucose-potentiated insulin secretion in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701989

7 January 2021

Stimulation of insulin secretion by efaroxan may involve interaction with potassium channels

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701989

7 January 2021

The α2-adrenoceptor antagonist efaroxan modulates K+ATP channels in insulin-secreting cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701989

7 January 2021

Predominant role of gluconeogenesis in increased hepatic glucose production in NIDDM.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701989

7 January 2021

Pathogenesis of NIDDM. A balanced overview

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701989

7 January 2021

Imidazoline receptors, non-adrenergic idazoxan binding sites and alpha 2-adrenoceptors in the human central nervous system

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701989

7 January 2021

Pharmacological characterization of I1 and I2 imidazoline receptors in human striatum

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701989

7 January 2021

Oral hypoglycemic agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701989

7 January 2021

Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701989

7 January 2021

Initial phase II clinical studies on midaglizole (DG-5128). A new hypoglycemic agent

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701989

7 January 2021

Natural history of beta-cell dysfunction in NIDDM.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701989

7 January 2021

Pancreatic Neuroendocrinology: Peripheral Neural Mechanisms in the Regulation of the Islets of Langerhans*

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701989

7 January 2021

A role for alpha-adrenergic receptors in abnormal insulin secretion in diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701989

7 January 2021

Design and synthesis of imidazoline derivatives active on glucose homeostasis in a rat model of type II diabetes. 1. Synthesis and biological activities of N-benzyl-N'-(arylalkyl)-2-(4',5'-dihydro-1'H-imidazol-2'-yl)piperazines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701989

7 January 2021

Measurement of cardiac left ventricular pressure in conscious rats using a fluid-filled catheter

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701989

7 January 2021

An insulin-releasing property of imidazoline derivatives is not limited to compounds that block alpha-adrenoceptors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701989

7 January 2021

Imidazoline compounds stimulate insulin release by inhibition of K(ATP) channels and interaction with the exocytotic machinery

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701989

7 January 2021

Identifiers

DOI

10.1038/SJ.BJP.0701989

1 reference

release_cqxzpx3ij5h7rdrgnwzik7fbgu

13 October 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/cqxzpx3ij5h7rdrgnwzik7fbgu

24 November 2022

mapped directly with Wikidata item

1 reference

13 October 2017

PubMed publication ID

9756373

1 reference